Physician profile
Chung Yu
NPI 1235394842
$2,855.59
in general payments reported to CMS, 2019-2025
22 companies · $604 in 2025
The $604 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $82.93 · 2021: $175 · 2022: $790 · 2023: $340 · 2024: $690 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.72 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $660.00 | 2022 | |
| Sight Sciences, INC. | $423.00 | 2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $334.85 | 2019-2025 | Cequa |
| Alcon Vision LLC | $158.36 | 2023-2025 | Rocklatan, Clareon, Rhopressa |
| Rxsight INC | $152.03 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Oyster Point Pharma, INC. | $151.55 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $127.35 | 2025 | |
| Bausch & Lomb Americas INC. | $121.04 | 2023-2024 | Vyzulta, Prolensa, Lotemax Sm |
| Harrow Eye, LLC | $103.32 | 2024-2025 | Vevye |
| Allergan, INC. | $95.19 | 2019-2021 | |
| Amgen INC. | $85.46 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $85.16 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $85.04 | 2021-2023 | |
| Tarsus Pharmaceuticals, INC. | $66.96 | 2024-2025 | Xdemvy |
| Abbvie INC. | $47.14 | 2022-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $32.63 | 2021-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $29.15 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.18 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $23.44 | 2019 | |
| Genentech USA, INC. | $18.95 | 2022 | |
| Thea Pharma INC. | $13.75 | 2024 | Iyuzeh |
| Horizon Therapeutics Plc | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chung Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.